Mixed results for Sanofi-Aventis: insomnia study good, antidepressant faces setback
French drug major Sanofi-Aventis has reported data from ongoing trials for three of its pipeline candidates. The GEMS and NOCTURNE studies on insomnia drugs eplivanserin and volinanserin, respectively, have shown positive outcomes, whereas the INDIGO study, investigating the safety and efficacy of antidepressant saredutant on the elderly, did not reach significance versus placebo. Lastly, the firm said the final results of the ATHENA study on Multaq (dronedarone) would be presented later this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze